AX-2025-018900 · Kisspeptin-10 · TFS lot TFS-{CAT}-9204

Section 1

Results

Measured against the index acceptance specification for the melanocortin-receptor peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 15 min gradient, 214 nm	99.53	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.47	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — C-terminal free acid (+1 Da)	0.28	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	1301.6300	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	1301.6270	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-2.3	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	90.95	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	90.52	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	5.43	mg	5 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	4.915	mg	5 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	98.3	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	3.93	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.88	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.24	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.45	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 15 min gradient	4.90	min	4.94 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.98	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	52,944	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Trp]-epimer	0.69	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 15 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 52,944, and skew follows the reported asymmetry factor of 0.98. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.28 % impurity against a 99.53 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Kisspeptin-10 — main peak	4.90	4,837,467	99.53	—
2	C-terminal free acid (+1 Da)	4.99	13,609	0.28	+0.984
3	oxidised Trp (+16 Da)	4.73	3,888	0.08	+15.995
4	[D-Trp]-epimer	4.84	2,916	0.06	0.000
5	des-Tyr (−163 Da)	4.62	2,430	0.05	-163.063
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 1301.6300 Da, computed from C63H83N17O14. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 1301.6270 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
3+	434.8839	434.8829	-0.0010	8.6
2+	651.8223	651.8208	-0.0015	50.0
1+	1302.6373	1302.6343	-0.0030	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	3.93
Counter-ion (acetate)	ion chromatography	4.88
Residual solvent + inorganic residue	estimated	0.24
Total peptide content	by difference	90.95
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.34	99.53	divergence +0.24 pp vs batch median
Total impurities (% area)	0.66	0.47
Largest single impurity (% area)	0.43	0.28
Water (%)	not stated	3.93
Counter-ion (%)	5.4	4.88
Peptide content (%w/w)	90.5	90.95
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → third-party forwarder (26 d) → laboratory (courier, cold pack, 12 d) → assay.
Assay date: 14 Nov 2025
Submitted to the index: 02 Dec 2025
Laboratory: Kestrel Bioanalytical, Melbourne, Australia
Method basis: 15 min gradient · unit-resolution MS
Verification status: METHOD LIMITED

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
That mass-identical impurities are absent. The gradient used is shorter than the index reference method and does not resolve the diastereomers named in the compound fingerprint. The purity figure is an upper bound.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

c18_2p602 Dec 2025

Column chemistry flatters or punishes a figure like this. A core-shell column at this gradient resolves the close-eluting family that a fully porous 5 µm bed merges, so 99.53 % here is a harder number than the same figure from a coarser column.

buyer_sourced02 Dec 2025

Provenance and purity together are what make a figure like this usable. An independently purchased vial at 99.53 % is worth several supplier-selected ones.

Section 7

Related records

Same batch — lot TFS-{CAT}-9204 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-018892	TFS-{CAT}-9204	Medutest	2025-Q4	98.90	3.20	—	Buyer-sourced	1	FAIL
AX-2025-018893	TFS-{CAT}-9204	Kestrel	2025-Q4	99.60	3.68	95.8	Buyer-sourced	1	FAIL
AX-2025-018894	TFS-{CAT}-9204	PeptideMeter	2025-Q4	99.10	4.03	100.8	Buyer-sourced	0	PASS
AX-2025-018895	TFS-{CAT}-9204	PeptideMeter	2025-Q4	99.28	4.03	93.6	Buyer-sourced	0	PASS
AX-2025-018896	TFS-{CAT}-9204	Medutest	2025-Q4	98.71	3.40	103.4	Buyer-sourced	0	PASS
AX-2025-018897	TFS-{CAT}-9204	Nordanalyt	2025-Q4	98.98	3.86	—	Buyer-sourced	0	PASS
AX-2025-018898	TFS-{CAT}-9204	Janoshik	2025-Q4	99.16	3.41	—	Buyer-sourced	0	PASS
AX-2025-018899	TFS-{CAT}-9204	Janoshik	2025-Q4	99.06	4.02	89.8	Buyer-sourced	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Kisspeptin-10 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043179	GL Biochem	GLBI-2608-N7715	Medutest	2026-Q3	98.97	4.37	—	Buyer-sourced	1	MARGINAL
AX-2026-043178	GL Biochem	GLBI-2608-N7715	Janoshik	2026-Q3	98.50	4.55	—	Buyer-sourced	1	MARGINAL
AX-2026-043184	GL Biochem	GLBI-2608-N7715	Janoshik	2026-Q3	98.99	3.63	100.6	Supplier-supplied	1	MARGINAL
AX-2026-043185	GL Biochem	GLBI-2608-N7715	Medutest	2026-Q3	98.71	3.71	107.0	Buyer-sourced	1	MARGINAL
AX-2026-043182	GL Biochem	GLBI-2608-N7715	Janoshik	2026-Q3	98.93	3.86	95.7	Buyer-sourced	1	MARGINAL
AX-2026-043183	GL Biochem	GLBI-2608-N7715	PeptideMeter	2026-Q3	98.54	4.17	102.2	Buyer-sourced	1	MARGINAL
AX-2026-043186	GL Biochem	GLBI-2608-N7715	Janoshik	2026-Q3	98.56	3.60	96.8	Buyer-sourced	1	MARGINAL
AX-2026-043181	GL Biochem	GLBI-2608-N7715	Janoshik	2026-Q3	98.77	4.06	95.2	Buyer-sourced	1	MARGINAL

Other recent TFS records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041681	CJC-1295 with DAC	TFS-{CAT}-9675	PeptideMeter	2026-Q3	98.82	3.67	—	Buyer-sourced	0	PASS
AX-2026-041766	BPC-157	TFS-{CAT}-1156	Janoshik	2026-Q3	99.54	6.34	—	Buyer-sourced	1	MARGINAL
AX-2026-041682	CJC-1295 with DAC	TFS-{CAT}-9675	Nordanalyt	2026-Q3	98.94	3.24	—	Buyer-sourced	0	PASS
AX-2026-041683	CJC-1295 with DAC	TFS-{CAT}-9675	Medutest	2026-Q3	98.68	3.46	97.0	Buyer-sourced	0	PASS
AX-2026-041765	BPC-157	TFS-{CAT}-1156	Janoshik	2026-Q3	99.79	6.01	—	Buyer-sourced	0	PASS
AX-2026-041680	CJC-1295 with DAC	TFS-{CAT}-9675	Medutest	2026-Q3	99.18	2.85	100.4	Buyer-sourced	0	PASS
AX-2026-041691	Semaglutide	TFS-{CAT}-9744	Janoshik	2026-Q2	98.31	6.07	91.4	Buyer-sourced	0	PASS
AX-2026-041700	SS-31 (Elamipretide)	TFS-{CAT}-1142	Medutest	2026-Q2	99.75	2.27	96.3	Buyer-sourced	0	PASS